@Article{oncologie.2022.023641,
AUTHOR = {Xue Cui, Min Peng, Honglei Chen},
TITLE = {The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy},
JOURNAL = {Oncologie},
VOLUME = {24},
YEAR = {2022},
NUMBER = {4},
PAGES = {665--678},
URL = {http://www.techscience.com/oncologie/v24n4/51004},
ISSN = {1765-2839},
ABSTRACT = {The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to
cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is
undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors,
researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these
promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory
co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy with LAG-3 is a hot topic, but its limitations in clinical application are also evident. This review
briefly describes the molecular structure, biological functions of LAG-3 in the immune cells and cancer cells and
prognosis significance, and then an overview of relevant ongoing clinical trials.},
DOI = {10.32604/oncologie.2022.023641}
}